Search - tctmd.com

Displaying 181 - 200 of 249

Sort: Relevancy | Date

News Conference News ESC 2018

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

Michael O'Riordan

August 26, 2018

News Daily News

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

Michael O'Riordan

August 16, 2018

News Daily News

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

Caitlin E. Cox

August 15, 2018

News Daily News

New AHA Advisory Waffles on Artificially Sweetened Drinks, Citing Dearth of Studies

Lucy Hicks

August 07, 2018

News Daily News

Less Stroke With PCI at 5 Years, but CABG Risks Front-loaded in First 30 Days

Michael O'Riordan

July 19, 2018

News Daily News

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

Todd Neale

July 02, 2018

News Conference News EAS 2018

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

Yael L. Maxwell

May 16, 2018

News Conference News EAS 2018

EAS Consensus Document Examines Safety of Statins Beyond Muscle Symptoms

Yael L. Maxwell

May 11, 2018

News Daily News

Less Aggressive HbA1c Targets Recommended by American College of Physicians

Michael O'Riordan

March 06, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Daily News

Diabetes, Multivessel CAD, and LV Dysfunction? Registry Analysis Gives CABG the Edge Over PCI

Michael O'Riordan

February 20, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

USPSTF Upholds Stance Against Hormone Therapy to Prevent Chronic Diseases in Menopausal Women

Caitlin E. Cox

December 12, 2017

News Conference News AHA 2017

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Michael O'Riordan

November 17, 2017

News Daily News

Statins and Diabetes: Causal Link Reinforced in New Analysis

Michael O'Riordan

October 25, 2017

Presentation

Global Geographic Variation in Patient Characteristics in PCI Clinical Trials

September 15, 2017

News Daily News

Patients in PCI Trials Vary Around the World, With Women Still Underrepresented

Michael O'Riordan

September 15, 2017

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

News Conference News ESC 2017

CABG Appears Superior to PCI for Patients With Type 1 Diabetes, Multivessel Disease

Todd Neale

August 26, 2017

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

Advertisement

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

New AHA Advisory Waffles on Artificially Sweetened Drinks, Citing Dearth of Studies

Less Stroke With PCI at 5 Years, but CABG Risks Front-loaded in First 30 Days

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

EAS Consensus Document Examines Safety of Statins Beyond Muscle Symptoms

Less Aggressive HbA1c Targets Recommended by American College of Physicians

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Diabetes, Multivessel CAD, and LV Dysfunction? Registry Analysis Gives CABG the Edge Over PCI

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

USPSTF Upholds Stance Against Hormone Therapy to Prevent Chronic Diseases in Menopausal Women

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Statins and Diabetes: Causal Link Reinforced in New Analysis

Global Geographic Variation in Patient Characteristics in PCI Clinical Trials

Patients in PCI Trials Vary Around the World, With Women Still Underrepresented

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

CABG Appears Superior to PCI for Patients With Type 1 Diabetes, Multivessel Disease

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content